Tetra Discovery Partners is a pharmaceutical drug development company development medicines for Alzheimer's Disease, Traumatic Brain Injury, and schizophrenia. The drugs in our pipeline offer a new mechanism focused on PDE4B and PDE4D.
Tetra designs drugs to treat memory loss and cognitive impairment by improving how the brain processes and stores information.
Tetra's promising drug for Alzheimer's Disease, BPN-14770, is being developed in partnership with the NIH Blueprint Therapeutics program.
Latest funding size
Time since last funding
|about 1 year|
|Grand Angels, Biosciences Research and Commercialization Center (BRCC), Muskegon Angels, Michigan Emerging Technology Fund, Michigan, J &J Investments, Dolby Family Ventures, Apjohn ventures|